In addition to the potential of enhancing endogenous anti-tumour immunity and improving the response to anti-PD-1 therapy, our studies also confirmed the therapeutic potential of targeting RIG-I in adoptive T-cell immunotherapy, especially in epitope-specific T cells of human origin. This evidence concerns the gene PDCD1 and neoplasm.